Rockwell Medical (RMTI) reported fourth quarter and full-year 2015 results after the bell this evening. The accompanying conference call was bizarre, and the stock is worth watching for a short.
Rockwell Medical received FDA approval for its lead asset Triferic last January (over one year ago), launching the product in September of 2015. Triferic is a dialysate add-in approved for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). The fourth quarter of last year was Triferic’s first on the market.
Already a Premium user? Sign In
